Compare · IRON vs NVO
IRON vs NVO
Side-by-side comparison of Disc Medicine Inc. (IRON) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRON and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 76.6x IRON ($2.91B).
- Over the past year, IRON is up 31.7% and NVO is down 21.8% - IRON leads by 53.5 points.
- IRON has been more active in the news (17 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 20 for IRON).
- Company
- Disc Medicine Inc.
- Novo Nordisk A/S
- Price
- $76.19+3.84%
- $50.31-2.25%
- Market cap
- $2.91B
- $222.81B
- 1M return
- +9.11%
- +15.47%
- 1Y return
- +31.75%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 17
- 5
- Recent ratings
- 20
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IRON
- Chief Executive Officer Quisel John D exercised 33,000 shares at a strike of $10.68 and sold $2,473,780 worth of shares (33,000 units at $74.96) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Disc Medicine Inc.
- Chief Operating Officer Yu Jonathan Yen-Wen exercised 100 shares at a strike of $13.50 and sold $8,250 worth of shares (100 units at $82.50) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Legal Officer Khara Rahul exercised 2,500 shares at a strike of $14.69 and sold $187,500 worth of shares (2,500 units at $75.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Yu Jonathan Yen-Wen sold $21,750 worth of shares (300 units at $72.50) as part of a pre-agreed trading plan and exercised 300 shares at a strike of $13.50 (SEC Form 4)
- Disc Medicine Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Chief Operating Officer Yu Jonathan Yen-Wen exercised 9,700 shares at a strike of $13.50 and sold $704,795 worth of shares (9,700 units at $72.66) as part of a pre-agreed trading plan (SEC Form 4)
- Disc Medicine Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Legal Officer Khara Rahul exercised 7,500 shares at a strike of $14.69 and sold $526,661 worth of shares (7,500 units at $70.22) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Quisel John D exercised 34,000 shares at a strike of $9.86 and sold $2,387,296 worth of shares (34,000 units at $70.21) as part of a pre-agreed trading plan (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S